Loading…
← CockpitCompetitor Analysis › FRE.DE Fresenius SE & Co. KGaAOpen in the cockpit ↗

Fresenius SE & Co. KGaAFRE.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Hospital/Nursing Management

German healthcare conglomerate running Helios hospitals, Kabi generic IV drugs/infusion products, and holding a majority stake in dialysis leader Fresenius Medical Care.

≈ Germany's HCA Healthcare + Baxter International combinedMomentum leader 97
Mkt cap
$32.7B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$53.5M
20-day average traded
Fwd P/E
14.7×
forward earnings
ROIC−WACC
-1.2 pp
WACC 6.4%
Hurdle
+16 pp
Req g minus delivered
Official | Implied
BBB / A+
agencies · bond market
Next earnings
98 days
24 Feb 2027
Close · EUR€53.43
1D-0.6%
1W+1.1%
1M+18.7%
3M+14.7%
6M+41.4%
YTD+9.1%
1Y+14.4%
ATR %2.1%
52w lowhigh2.2% off high

What Fresenius SE & Co. KGaA does

German healthcare conglomerate running Helios hospitals, Kabi generic IV drugs/infusion products, and holding a majority stake in dialysis leader Fresenius Medical Care.

Helios hospitals are paid mainly by public health insurers, while Kabi sells injectable generics and nutrition products to hospitals, so earnings depend on patient volumes and procurement prices. Since 2023 its holding in Fresenius Medical Care is accounted for as an investment rather than consolidated. The Else Kroener-Fresenius foundation is the largest shareholder.

In one line: Germany's HCA Healthcare + Baxter International combined.

Products and services

  • Helios hospitals (Germany, Spain)
  • Kabi (IV drugs, clinical nutrition, biosimilars)
  • Fresenius Medical Care stake (dialysis)
  • Vamed (health project management, being divested)

Customers

  • Hospitals & clinics
  • Patients (dialysis, hospital care)
  • Healthcare providers/distributors

Where it sits in the supply chain

  • Healthcare
  • Hospital operation + pharma…
  • Hospitals, IV drugs/nutrition, dialysis…

What could go right

  • Aging population healthcare demand
  • Biosimilar drug launches
  • Hospital margin improvement programs

What could go wrong

  • German hospital reimbursement pressure
  • Dialysis industry reimbursement risk (FMC)
  • Complex conglomerate structure discount

Moat: narrow (scale, installed base, regulatory licence). Large hospital network and generic injectable manufacturing scale, but competitive, low-margin segments.

Headquarters: Bad Homburg, Germany · Founded: 1912 · Employees: 178,394

Named competitors

Fresenius SE & Co. KGaA at a glance

Size Fresenius SE & Co. KGaA (FRE.DE) is a Germany Health Care company (Hospital/Nursing Management) with a market value of $32.7B, the 28th largest of 198 Germany companies the cockpit tracks. Shares closed at €53.43 on 18 Nov 2026.

Performance Over six months the shares gained 41.4%, against +16.9% for the median peer and -0.9% for the Germany market (cap-weighted) — 2nd highest of 7 in its peer set.

Growth Revenue grew 6.5% over the last twelve months (peer median +8.0%); the operating margin is 9.8% (peer median 15.3%).

Valuation It trades at 14.7× forward earnings against a peer median of 31.4× (3rd cheapest of 8).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -9%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.2 points below its cost of capital (6.4% WACC).

Credit Fresenius SE & Co. KGaA has 16 bonds outstanding ($9.82B), rated BBB by the agencies and trading like A+ at a weighted spread of 81 bp.

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026FRE.DE 145Peer median 118
Six months, rebased to 100: Fresenius SE & Co. KGaA against the median of its 7 peers (local-currency closes).

Fresenius SE & Co. KGaA financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€23.8B€22.9B€22.0B€21.1B€21.3B
Revenue growth—+4%+4%-1%—
Gross profit€6.14B€5.69B€5.64B€4.97B€5.20B
EBITDA€3.44B€3.30B€3.37B€2.74B€2.65B
Net income€1.55B€1.26B€471M-€594M€1.37B
Free cash flow€1.46B€1.20B€1.50B€3.28B€2.32B
Capital expenditure€1.38B€1.50B€1.06B€1.29B€2.00B
Total debt€11.8B€11.9B€13.6B€15.8B€27.8B

Quarterly statements and history in the cockpit →

Fresenius SE & Co. KGaA competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%+20%THCAPOLLOHOSPHCAUHSMAXHEALTHRHCFRE.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Fresenius SE & Co. KGaA is the large dot.

Fundamentals: revenue growth against valuation

+5%+10%+15%+20%+25%20×40×60×THCAPOLLOHOSPHCAUHSMAXHEALTHMANIPALHOSRHCFRE.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Fresenius SE & Co. KGaA is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%THCAPOLLOHOSPHCAUHSMAXHEALTHMANIPALHOSRHCFRE.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Fresenius SE & Co. KGaA is the large dot.

Fresenius SE & Co. KGaA competitors and peer comparison

Head to head with its named competitors (FRE.DE vs BAX vs HCA vs DVA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Fresenius SE & Co. KGaA FRE.DE$32.7B+41%+7%10%14.7×7.0%
Baxter International BAX$13.5B+39%+5%6%12.7×13.4%
HCA Healthcare HCA$99.5B+20%+6%15%15.6×3.1%
DaVita DVA$10.2B-18%+6%15%10.1×-2.5%

How Fresenius SE & Co. KGaA compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Fresenius SE & Co. KGaA against its 7 peers (data as of 18 Nov 2026)
MeasureFRE.DEPeer medianRank in peer set
1-month return+18.7%+2.3%2nd highest of 8
6-month return+41.4%+16.9%2nd highest of 7
Distance from 52-week high-2.2%-13.7%highest of 8
Revenue growth (TTM)+6.5%+8.0%4th lowest of 8
Operating margin9.8%15.3%2nd lowest of 8
Forward P/E14.7×31.4×3rd cheapest of 8
Growth the price implies (Req g, 7 yrs)7.0%14.0%4th least demanding of 8
Growth delivered (Del g)-8.8%+8.5%lowest of 8
Hurdle (Req g minus delivered)+15.8 pp+4.1 pp2nd most demanding of 8
ROIC minus cost of capital-1.2 pp+2.5 pp4th lowest of 8
EV / EBITDA11.7×10.7×4th most expensive of 8
Net debt / EBITDA2.9×2.2×3rd most indebted of 8
Bond spread81 bp123 bptightest of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Fresenius SE & Co. KGaA FRE.DEGermany$32.7B+41%+7%10%14.7×7.0%-8.8%
Tenet Healthcare THCUnited States$21.6B+45%+6%17%13.4×-1.4%+3.9%
Apollo Hospitals Enterprise APOLLOHOSP.NSIndia$13.6B+10%+19%12%51.0×33.3%+19.0%
HCA Healthcare HCAUnited States$99.5B+20%+6%15%15.6×3.1%+8.0%
Universal Health Services UHSUnited States$10.7B+13%+8%11%8.3×-1.8%+8.5%
Max Healthcare Institute MAXHEALTH.NSIndia$10.6B-4%+15%21%55.2×45.3%+27.2%
Manipal Health Enterprises MANIPALHOS.NSIndia$9.69Bn/a+25%19%66.5×32.9%+28.8%
Ramsay Health Care RHC.AXAustralia$8.31B+41%+4%5%31.4×14.0%+8.3%

Fresenius SE & Co. KGaA bonds and credit

Fresenius SE & Co. KGaA has 16 bonds outstanding with $9.82B face value. The agencies rate it BBB; its bonds trade like A+. Weighted yield 3.92%, a spread of 81 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Fresenius SE & Co. KGaA's main competitors?
Named competitors: Baxter International (BAX), HCA Healthcare (HCA), B. Braun (private) (private or unlisted), DaVita (DVA), Sana Kliniken (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Tenet Healthcare (THC), Apollo Hospitals Enterprise (APOLLOHOSP.NS), HCA Healthcare (HCA), Universal Health Services (UHS), Max Healthcare Institute (MAXHEALTH.NS), Manipal Health Enterprises (MANIPALHOS.NS).
Is Fresenius SE & Co. KGaA expensive compared with its peers?
On forward p/e it trades at 14.7× against a peer median of 31.4×, 3rd cheapest of 8 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -9%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Fresenius SE & Co. KGaA stock performed?
Over six months to 18 Nov 2026 the shares returned +41.4% against +16.9% for the median peer; over one year +14.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.